What Is New in HCM?
Program Goals
Disease Burden
Complications and Pathways of Disease Progression
Symptoms
Obstructive vs Nonobstructive HCM Assessment
Diagnostic Challenges
Approved Disease-Specific Therapy To Date: Only Propranolol
Symptomatic Nonobstructive HCM ACCF/AHA Treatment Algorithm
Symptomatic Obstructive HCM ACCF/AHA Treatment Algorithm
Evaluate for an Implantable Defibrillator
Investigational Therapies
Mavacamten (Formerly MYK-461)
Baseline Characteristics in PIONEER (Part A)
Primary Endpoint: Rapid Reduction in Post-Exercise LVOT Gradient
Significant Improvement in Peak VO2 by Week 12
Improvement in NYHA Functional Class
Research
Abbreviations